Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China

Xiao Liu1,2†, Yazhou Cui1,2† and Jinxiang Han1,2*

Abstract

Background: Multiple sclerosis (MS) is a rare chronically debilitating disease. There are few reports on the burden of disease of MS and prevalence in China. The authors intended to estimate disease burden and prevalence of MS in Shandong Province using available epidemiologic data.

Methods: Prevalence was calculated using DISMOD II software based on incidence extrapolated from hospitalization data, case fatality and remission rate from literature as input indexes. Disability-adjusted life year (DALY) was computed with epidemiologic indexes estimated by DISMOD II program.

Results: The prevalence of MS was estimated to be 3.7 (95 % CI: 1.65–5.8) and 6.7 (95 % CI: 2.7–9.56) cases per 100,000 people for males and for females, respectively. The mean age at onset of MS was 36.0 (43.0 ± 30.0 years in males and 33.7 (43.4 ± 29.7) years in females. Duration of the disease was estimated to be 34.0 (31.6 ± 21.0) years for males and 39.5 (34.9 ± 21.8) years for females. The disease burden in disability-adjusted life years was 3316, comprised of 903 (27.2 %) years of life lost (YLL) and 2413 (72.8 %) years lived with disability (YLD).

Conclusions: Our study highlighted that population in Shandong Province had a high prevalence of MS and the patients had a heavy disease burden. It also revealed that the results obtained in this paper would be useful to provide a reference for establishing specific healthcare policies for this rare disease in Shandong Province.

Keywords: Rare diseases, Prevalence, DISMDOII, Multiple sclerosis, DALY, Burden of disease, Shandong Province

Background

Multiple sclerosis (MS) is a rare disease, characterized by chronic course with intermittent relapses, usually ending up with a severe debilitation [1]. Therefore, once diagnosed, patients with MS are forced to live with it for the rest of their lives, leading to significant health, social, and economic problems [2, 3].

According to previous studies, the prevalence of MS has a wide variation. The estimated prevalence of MS is 203.4/100,000 in the United Kingdom and 94.7/100,000 in France, respectively [4, 5]. In the United States, the prevalence of MS has been presumed to be approximately 100/100,000 [5]. The prevalence of MS is estimated to be 3.9 per 100,000 in Japan and 3.5 per 100,000 in Korea [6, 7]. According to WHO, there are more than 2.5 million MS patients worldwide, accounting for 6.29 % of the total neurologic diseases and disease burden of MS accounts for 0.1 % of total disease burden of neurologic diseases. It has been estimated that MS generates 2.9 person-years per 100,000 in Korea [8, 9].

Even though MS is also an intractable and chronically debilitating rare disease in China, yet, until now, to the best of our knowledge, no studies on the prevalence and disease burden of MS are available. In addition, data from other countries may not reflect the country-specific situations. The lack of these important epidemiological

* Correspondence: lx881019@126.com
† Equal contributors
1 Shandong Medicinal Biotechnology Center, Key Laboratory for Biotech Drugs of the Ministry of Health, Key Laboratory for Rare Disease of Shandong Province, Shandong Academy of Medical Sciences, Jinan, Shandong, China
2 Jinan University Shandong Academy of Medical Sciences College of Life Science and Medicine, Jinan, Shandong, China

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
data has greatly limited the government to develop a health policy for MS. Therefore, estimation of epidemiologic indexes of MS in China is necessary. In this study, the DISMODII was employed to estimate the prevalence and disease burden of MS in Shandong Province, China.

DISMODII is structured by two basic inputs: the construction of population divided by gender and age, and the entire mortality rate for each demographic group. The model assumes a causal relationship between a set of indicators relevant by age and gender: incidence, prevalence, remission, mortality, duration, case fatality, and the relative risk on total mortality [10, 11]. If three of these disease variables (by age groups and gender) are defined, DISMODII uses a set of mathematical equations to derive an internally consistent set of epidemiological parameters including the prediction of the other disease parameters. In this study, incidence, case fatality and remission rate were used as the three inputs.

Methods

Estimation of MS incidence in Shandong Province

Currently, China has no MS disease registration system. In this study, we used the hospitalized patients of MS in 2013 to estimate the incidence of MS in Shandong Province. The study was approved by the Shandong Academy of Medical Sciences’ ethics committees. All data used in this study were accessed in accordance with ethical requirements and did not violate the privacy right of individuals. The hospitalization data were obtained from university-affiliated hospitals, and hospitals at provincial or municipal level from 17 cities in Shandong Province in a national pilot project of rare diseases initiated in China. The system contains registration files of hospitalized patients, which include comprehensive records of demographic data, dates of clinical visits, diagnostic codes, details of prescriptions, and examinations. Based on International Classification of Diseases Ten Revision (ICD-10) code, we collected the patients diagnosed with MS from the system and excluded those patients with uncertainty or repeated registrations. The incidence of MS was calculated using the number of incident cases as the numerator and the Shandong population in 2013 as the denominator.

Case fatality rate

Since case fatality rate is currently unavailable in China, the relevant data of case fatality rate were obtained from published research from Korea [9]. Data from Korea were used as the reference were based on the following considerations: on the one hand, Korea is the neighboring country with the closest racial comparisons to China in Asia; on the other hand previous studies have demonstrated that there is no significant correlation between survival rate and latitude of regions among Asian races and that the pathogenesis characteristics such as disease’s progress and age are of little difference.

Other data sources

Remission rate refers to a fraction of individuals with a disease recovering to a normal state. Since MS is assumed to be an irreversible disease, the remission rate is deemed to be equal to zero [12]. The age- and gender-specific population of Shandong Province was obtained from the Statistics Office. Data on overall mortality were drawn from Chinese Center for Disease Control and Prevention.

Data analysis using DISMOD II software

To estimate prevalence and other epidemiologic data, all data were broken down by age and gender. Incidence, the case fatality and the remission rate, along with general mortality and population were entered into DISMODII. The equation calculated numerically using the finite difference, an iterative approximation method. For estimation purposes, the estimators were assumed to follow a Poisson distribution.

Burden of disease

To estimate the disease burden, we adopted the approach used in the Global Burden of Disease study, which has been used to estimate rare disease burden in China [13]. According to this approach, DALY was the sum of years of life lost (YLL) and years lived with disability (YLD). To calculate the YLD, number of incident cases, disease duration, disability weight and age at onset were entered into formula. The number of fatal cases and the remaining life expectancy were added to the YLL formula for calculation.

\[
YLL = \sum_{0}^{t} D_i \times E_i \\
YLD = \sum_{0}^{t} N_i \times I_i \times T_i \times D
\]

Where \( E_i \) is the average expected years remaining, \( D_i \) the number of deaths, \( N_i \) the population susceptible to MS at each age, \( I_i \) MS incidence by age group and sex, \( T_i \) disease duration for each age group, and \( D \) is disability weight.

In this study, the Coale and Demeny West Level 26 Life Table was adopted to calculate the remaining life expectancy [14]. Regarding to disability weight, no data have been published in China. Therefore, a disability weight value of 0.690 was adopted in this study. This value was used for analysis of burden of disease of MS patients in Korea [9]. The age-weighting and discounting factors used in the GBD study were applied to calculate DALY. In summary, DALY was calculated with a
discount rate of 3\%, an age-weighting modulation factor of \( k = 1 \) \( D \), and a disability weight of 0.69.

**Statistical analysis**

All statistical analyses are carried out using SPSS 20.0 statistical software. The results are expressed as 95\% confidence intervals (95\% CI) for prevalence. Mean ± SD for are used to express continuous variables.

**Results**

Based on the hospitalization data, a set of patients diagnosed with MS for the first time in 2013 were obtained, which were used to estimate the incidence of MS. As seen in Table 1, this study demonstrated an increasing incidence of MS with the increase in ages, peaking at ages 15–29 years and 30–44 years for female and male patients, respectively. Generally, female patients had an earlier onset and higher incidence than male patients.

In this research, the prevalence of MS was estimated to be 3.7(95\% CI: 1.65–5.8) cases per 100,000 people for males and 6.7(95\% CI: 2.7–9.56) cases per 100,000 people for females (Table 2). Furthermore, the prevalence tended to increase in both men and women with the increase in ages, reaching a peak at age 45–59 years for both sexes. The mean disease duration of MS was 34.0 and 39.5 years in males and females, respectively. It was also estimated that female patients had an average onset age of 33.7 years, which was slightly earlier than the male patients (36 years) (Table 2).

The DALY rate of MS in the Shandong population was 3.46 person-years per 100,000. The DALY rate of women (4.46DALYs/100,000) was higher than that in men (2.47DALYs/100,000). Moreover, DALYs in males and females were both the highest in the age of 30–44 years (Table 3). In addition, as shown in Table 3, YLL was 308 for males and 595 for females, whereas YLD was 891 for males and 1515 for females, with a total of 3316. As seen in Fig. 1, it could be seen that different groups of age and gender contributed significantly differently to DALY. With the increase in ages, the percentage of DALY increased due to mortality (YLL). Nevertheless, for patients aged 59 years or younger, the most important factor to DALY was morbidity.

**Discussion**

Although rare disease study is becoming more and more interesting, the exploration of rare diseases epidemiology is still novel in the field [15]. The obtaining of rare disease epidemiological data mainly depends on the disease registration system or extrapolation from other data resources. Currently, there is no specific registration system for rare diseases in China, and the important epidemiological data, especially the prevalence and disease burden of most rare diseases, are lacking. It has been generally acknowledged that such situation represents a major challenge for China to develop its medical policies on rare diseases [16, 17].

The study uses an extrapolation approach based on DISMOD II program to estimate disease burden and prevalence of MS in Shandong Province, China. This strategy has been applied to scleroderma and schizophrenia in the previous studies [18, 19]. Representative epidemiological indexes were input into the DISMOD model, and it was found that both inputs and outputs had almost the same distribution, indicating a sufficient validity and reliability of this strategy. In this study, a duration of disease of 34.0 and 39.5 years for males and females, respectively, which was very well in line with that reported in other countries. For example, the duration of disease is 32.5–49.2 years in Canadian and 36 for men and 43 years for women in Norway [20–22], supporting the validity of this study.

| Table 1 | Input variables in DISMOD II modeling for multiple sclerosis in Shandong Province |
|---|---|---|---|
| **Age** | **Input** | **Incidence \(^a\)(100000)** | **Case fatality (100000)** |
| | | Male | Female | Male | Female |
| 0–4 | 0.07 | 0.07 | 0.012 | 0.007 | 2937849 | 2396888 |
| 5–14 | 0.06 | 0.09 | 0.012 | 0.007 | 5210843 | 4528629 |
| 15–29 | 0.12 | 0.36 | 62.7 | 47.6 | 11096477 | 10788151 |
| 30–44 | 0.23 | 0.28 | 607.6 | 509.5 | 11963422 | 11776850 |
| 45–59 | 0.11 | 0.13 | 1312.2 | 1364.0 | 10505956 | 10457193 |
| 60–69 | 0.05 | 0.05 | 2046.6 | 1864.5 | 3911022 | 3936225 |
| 70–79 | 0.14 | 0.08 | 2257.7 | 1574.8 | 2119215 | 2342429 |
| 80+ | 0.0007 | 0.0007 | 1979.9 | 2062.5 | 702160 | 1119410 |
| **Total** | 0.098 | 0.13 | NA | NA | 48446944 | 47345775 |

\(^a\)Incidence was estimated using the number of hospitalized patients as the numerator and the Shandong Province population in 2013 as the denominator

\(^b\)Shandong population in 2013
A prevalence of MS of 5.2/100,000 people was obtained in Shandong in this study, which was higher than that in Japan (3.9/100,000) and Korea (3.5/100,000), and much lower than that in European countries (203.4/100,000 in United Kingdom, 94.7/100,000 in France) and the United States (100/100,000). It should be noted that the incidence of MS was calculated in this study with the hospitalization data against Shandong population, it is inevitable that those outpatients diagnosed with MS would not be included and some other patients with MS might be hospitalized in other hospitals that were not covered in this study. Therefore, the parameters of MS we used in this study might represent the low limit and the prevalence of MS obtained should be regarded as the lowest prevalence in Shandong Province.

Incidence and prevalence are often used as one measure index of disease frequency since their calculation only concerns the number of cases and the basic population. However, DALYs consider not only survival time but also life quality caused by a certain disease and their calculation requires age and sex dependent incidence, case fatality, severity of disease and life expectancy. Therefore, DALY is a more comprehensive health indicator to demonstrate the threat of some disease to the whole population. In this study, the major contributing factor to DALY was YLD, indicating that most of the burden of disease was from the loss due to disability from the disease. This result demonstrated that MS could cause high disease burden since it occurs mainly at childbearing age. The DALY rate was estimated to be3.46 person-years per 100,000 in Shandong, which was slightly higher than that reported in Korea(2.9 person-years per 100,000) [9], therefore, more attention should be paid to MS in Shandong Province with the limited health resources.

In our study, we provide clear evidence that there is a large population of MS patients with a high disease burden in Shandong Province. Despite the lack of specific treatment to cure MS, some orphan drugs have been validated to bring about a notable improvement in quality of life. However, most of the orphan drugs targeting MS are still unavailable in China. We believe that these

Table 2 Modeled incidence (per 100000 population), prevalence (per 100000 population), age on set, death cases and disease duration by age groups and gender

| Age | Incidence | Prevalence | Duration (yr) | Age of onset (yr) | Death cases |
|-----|-----------|------------|---------------|------------------|-------------|
|     | Male      | Female     | Male          | Female           | Male        | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| 0–4 | 0.07      | 0.07       | 0.18          | 0.18             | 63.7        | 68.3    | 2.5   | 2.5    | 0    | 0    |
| 5–14| 0.06      | 0.09       | 0.67          | 0.8              | 56.9        | 61.0    | 9.5   | 10.0   | 0    | 0    |
| 15–29| 0.12     | 0.37       | 1.6           | 3.1              | 42.8        | 46.3    | 24.1  | 25.0   | 0    | 0    |
| 30–44| 0.22     | 0.27       | 4.7           | 8.9              | 32.1        | 35.7    | 36.7  | 37.2   | 4    | 6    |
| 45–59| 0.12     | 0.14       | 6.2           | 10.4             | 22.7        | 26.1    | 50.2  | 50.4   | 8    | 15   |
| 60–69| 0.05     | 0.05       | 5.8           | 9.4              | 14.4        | 18.0    | 65.1  | 65.0   | 5    | 7    |
| 70–79| 0.13     | 0.08       | 5.4           | 8.5              | 10.5        | 13.4    | 75.7  | 75.0   | 3    | 3    |
| 80+ | 0.02      | 0.02       | 5.3           | 7.8              | 9.8         | 10.6    | 82.5  | 82.5   | 1    | 1    |
| Total| 0.12      | 0.2        | 3.7           | 6.7              | 34.0        | 39.5    | 36.0  | 33.7   | 21   | 32   |

Table 3 Years of life lost (YLL), years lived with disability (YLD) and disability-adjusted life year (DALY) due to multiple sclerosis in Shandong Province

| Age | Male | Female | Total |
|-----|------|--------|-------|
|     | YLL  | YLD    | DALY  |
| 0–4 | 0    | 40     | 40    |
| 5–14| 0    | 57     | 57    |
| 15–29| 0     | 236    | 236   |
| 30–44| 70   | 374    | 444   |
| 45–59| 151  | 149    | 300   |
| 60–69| 69   | 16     | 85    |
| 70–79| 18   | 19     | 37    |
| 80+  | 0    | 0      | 0     |
| Total| 308  | 891    | 1199  |

Liu et al. Orphanet Journal of Rare Diseases (2016) 11:73
epidemiologic data obtained in this study will contribute to provide a reference for the development of specific health policies on MS in the future. In addition, these indexes can serve as the basis of epidemiological data for individual disease that can fill in the gap of research on rare diseases whose research has been lagging in China. This evidence-based study on MS will also be useful for promoting industry to research and develop innovative orphan drugs for the treatment of this devastating rare disease.

Although our results are promising, the limitations of the present study should be addressed. The first is that the effects of some factors, such as social and economic status, health services and environmental hygiene, were not quantified precisely. With this regard, the WHO standards, the widely accepted world standards, were adopted in this study. However, there are some discrepancies between the standards and the actual domestic environment. The second is that the data used to calculate incidence are insufficient. However, the reality in China is that rare disease data are divided into different age groups or come with restrictive conditions, making it difficult to use them. In addition, previous study has demonstrated that 92.5 % of rare diseases are diagnosed in university hospitals, provincial hospitals, and municipal hospitals [16]. And China has taken a series of effective measures and attempts to improve the diagnosis of rare diseases [23]. Therefore, the incidence obtained in this study is appropriate for use. In the future, we would collect more MS information to complement this study. We believe when these data become available, we can estimate epidemiological parameters more precisely.

### Conclusion

In this study, using a DISMODII model, we estimated prevalence and disease burden of MS in Shandong Province. Our data indicate that there are a large number of MS patients with high disease burden in Shandong Province, and that the current healthcare policies need to be emphasized on this severe rare disease. The result of this paper also contributes significantly to the international readers because there are no reports available for them on the prevalence and disease burden of MS in China.

### Abbreviations

CDC, Centers for disease prevention and control; CI, confidence intervals; DALY, disability-adjusted life years; MS, multiple sclerosis; YLD, years lived with disability; YLL, years of life lost

### Acknowledgments

This work was supported by the Key Projects in the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2013BAI07B02).

### Authors’ contributions

JH and YC put forward the idea and designed the key points. XL and YC performed data analysis and wrote the paper. All authors read and approved the final manuscript.

### Competing interest

The authors declare that they have no competing interests.

### Ethics approval and consent to participate

The study was approved by the Shandong Academy of Medical Sciences’ ethics committees.

Received: 20 January 2016 Accepted: 27 May 2016
Published online: 04 June 2016

### References

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
2. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple
sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19:e11–25.
3. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 1994;13:1–7.
4. MacKenzie S, Monant SV, Bloomfield GA, MacDonald TM, O’Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85:76–84.
5. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2015;172(1):3–13. doi:10.1016/j.neurol.2015.10.006.
6. Kita J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003;2:117–27.
7. Kim NH, Kim HJ, Cheong HK, Kim BJ, Lee KH, Kim EH, Kim EA, Kim S, Park MS, Yoon WT. Prevalence of multiple sclerosis in Korea. Neurology. 2010;75:1432–8.
8. Murray CJL, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1996. p. 1–98.
9. Chung SE, Cheong HK, Park JH, Kim HJ. Burden of disease of multiple sclerosis in Korea. Epidemiol Health. 2012;34, e2012008.
10. Kruitshaar ME, Barendrecht JJ, Hoeymans N. The use of models in the estimation of disease epidemiology. Bull World Health Organ. 2002;80:622–8.
11. Barendrecht JJ, Van Oortmerssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1:4.
12. Organization WH. Neurological disorders: public health challenges. Geneva: World Health Organization; 2006. p. 27–37.
13. Yang LP, Liang SY, Wang XI, Li XJ, Wu YL, Ma W. Burden of disease measured by disability-adjusted life years and a disease forecasting time series model of scrub typhus in Laiwu, China. PLoS Negl Trop Dis. 2015;9, e3420.
14. Coale AGG. Revised regional model life tables at very low levels of mortality. Popul Index. 1989;55:613–43.
15. de la Paz MP, Villaverde-Hueso A, Alonso V, Janos S, Zurriaga O, Pollan M, Abaitua-Borda I. Rare diseases epidemiology research. Adv Exp Med Biol. 2010;686:17–39.
16. Cui Y, Zhao H, Liu Z, Liu C, Luan J, Zhou X, Han J. A systematic review of genetic skeletal disorders reported in Chinese biomedical journals between 1978 and 2012. Orphanet J Rare Dis. 2012;7:55.
17. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Intractable and rare diseases research in Asia. Biosci Trends. 2012;6:48–51.
18. Phanthunane P, Vos T, Whiteford H, Bertram M, Udomsat P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010;8:24.
19. Villaverde-Hueso A, Sanchez-Vallie E, Alvarez E, Morant C, Carreira PE, Martin-Arribas MC, Genova R, Ramirez-Gonzalez A, de la Paz MP. Estimating the burden of scleroderma disease in Spain. J Rheumatol. 2007;34:2236–42.
20. Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BM, Leufkens HG, De Boer A, De Vries F. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol. 2012;19:1007–14.
21. Kingswell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012;83:1–6.
22. Ragoneese P, Aridon P, Salemi G, D’Amelio M, Savetierre G. Mortality in multiple sclerosis: a review. Eur J Neurol. 2008;15:123–7.
23. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012;1:3–9.